Company profile: Polyplus Transfection
1.1 - Company Overview
Company description
- Provider of innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids for research, bioproduction and therapeutics, including transfection reagents for lentiviral (FectoVIR®-LV) and AAV production (FectoVIR®-AAV), PEIpro® for viral vector bioproduction, in vivo–jetPEI®, LipidBrick® Library for LNP formulation, and in vivo-jetRNA®+ for mRNA/saRNA delivery.
Products and services
- FectoVIR®-AAV: AAV-focused transfection reagent that produces adeno-associated viral vectors for nucleic acid delivery in research, bioproduction and therapeutics
- FectoVIR®-LV: Lentiviral transfection reagent engineered to improve lentiviral yields and reduce DNA required during vector production for nucleic acid delivery
- PEIpro®: Bioproduction transfection reagent used in the bioproduction industry for the production of viral vectors supporting research and therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Polyplus Transfection
BlinkBio
HQ: United States
Website
- Description: Provider of specialized bioorthogonal chemistries for the delivery of next-generation medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlinkBio company profile →
Fluorogenics
HQ: United Kingdom
Website
- Description: Provider of cutting-edge sample-to-result integrated analyzers and real-time PCR lyophilized reagents, bringing technical expertise to these solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluorogenics company profile →
NeuMoDx Molecular
HQ: United States
Website
- Description: Provider of molecular diagnostic (MDx) testing solutions for hospital and clinical reference laboratories, including fully automated, continuous random-access analyzers (NeuMoDx 288 and 96) that integrate sample-to-result using proprietary NeuDry reagent technology, plus lysis buffers (3 and 4), an HBV quant test strip, and a GBS assay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuMoDx Molecular company profile →
List Labs
HQ: United States
Website
- Description: Provider of microbial CDMO services, offering end-to-end support from early-stage process development to cGMP manufacturing for Phase I & II clinical supply, and research reagents including nearly 100 bacterial toxins, polysaccharides, and antibodies. Also supplies anthrax (PA, EF, LF), botulinum, C. difficile (Toxin A/B), and cholera toxins, and specializes in native toxins, recombinant proteins, fermentation, and assay development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full List Labs company profile →
Andor
HQ: United Kingdom
Website
- Description: Provider of scientific imaging equipment, designing and manufacturing high-performance cameras (EMCCD, CCD, sCMOS), integrated multimodal confocal microscopy systems for life sciences, spectroscopy platforms based on Czerny-Turner or Echelle spectrometers with advanced detectors, optical cryostats (<3 K to 500 K), photostimulation tools, and imaging/analysis software for scientific research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Andor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Polyplus Transfection
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Polyplus Transfection
2.2 - Growth funds investing in similar companies to Polyplus Transfection
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Polyplus Transfection
4.2 - Public trading comparable groups for Polyplus Transfection
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →